Doximity (NYSE:DOCS) Given New $34.00 Price Target at Royal Bank Of Canada

Doximity (NYSE:DOCS) had its price target raised by research analysts at Royal Bank Of Canada from $28.00 to $34.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price points to a potential upside of 6.99% from the company’s previous close.

DOCS has been the topic of several other reports. Evercore set a $35.00 price objective on shares of Doximity in a research report on Tuesday, September 29th. Wolfe Research upgraded shares of Doximity to an “outperform” rating in a research report on Thursday, August 13th. Barclays upped their price target on shares of Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a report on Friday, August 21st. Weiss Ratings raised shares of Doximity from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, October 6th. Finally, BMO Capital Markets reiterated a “market perform” rating and issued a $30.00 price target on shares of Doximity in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $30.27.

Doximity Price Performance

DOCS traded down $1.40 during trading on Friday, reaching $31.78. 2,332,285 shares of the stock were exchanged, compared to its average volume of 3,881,142. The company has a market capitalization of $5.66 billion, a price-to-earnings ratio of 37.31, a P/E/G ratio of 27.12 and a beta of 1.29. Doximity has a 1 year low of $17.15 and a 1 year high of $58.24. The business’s 50 day moving average price is $28.95 and its two-hundred day moving average price is $25.55.

Doximity (NYSE:DOCS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. The business had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.36 EPS. On average, analysts anticipate that Doximity will post 0.74 EPS for the current year.

Insider Buying and Selling

In other Doximity news, Director Watkin Phoebe L. Yang sold 1,290 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the transaction, the director directly owned 24,744 shares in the company, valued at approximately $660,912.24. The trade was a 4.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kira Wampler sold 2,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $32.89, for a total value of $65,780.00. Following the transaction, the director directly owned 27,923 shares in the company, valued at approximately $918,387.47. This represents a 6.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 13,750 shares of company stock worth $386,310. 31.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Doximity

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP lifted its position in Doximity by 29.3% during the third quarter. Allworth Financial LP now owns 2,642 shares of the company’s stock worth $75,000 after buying an additional 599 shares during the period. Russell Investments Group Ltd. boosted its stake in Doximity by 5.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 117,733 shares of the company’s stock worth $3,337,000 after buying an additional 6,481 shares during the last quarter. Jefferies Financial Group Inc. boosted its stake in Doximity by 526.3% in the 3rd quarter. Jefferies Financial Group Inc. now owns 179,400 shares of the company’s stock worth $5,084,000 after buying an additional 150,755 shares during the last quarter. Riverbridge Partners LLC grew its holdings in Doximity by 7.9% in the 3rd quarter. Riverbridge Partners LLC now owns 303,539 shares of the company’s stock valued at $8,602,000 after buying an additional 22,320 shares during the period. Finally, Lido Advisors LLC purchased a new stake in Doximity in the 3rd quarter valued at about $281,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Key Stories Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported fiscal Q2 2027 revenue of $174.5 million and earnings of $0.36 per share, beating estimates. It also forecast Q3 revenue of $195–$196 million and fiscal 2027 revenue of $678–$683 million, both above consensus. Management cited record engagement, a 51% adjusted EBITDA margin, and more than 190 health systems purchasing its AI suite. Fiscal 2027 Q2 results
• Positive Sentiment: Needham reaffirmed its Buy rating and $41 price target, signaling potential upside from the current share price. Needham analyst rating
• Negative Sentiment: The stock’s weak response contrasts with the earnings beat. Quarterly revenue grew 3.6% year over year, while EPS declined from $0.45 a year earlier to $0.36—potentially raising concerns about the pace of growth and earnings trends. Doximity quarterly results and stock reaction
• Negative Sentiment: Several law firms highlighted a securities class action and the November 16 lead-plaintiff deadline. The complaint alleges that Doximity misrepresented the contribution of its Newsfeed advertising product to growth; these claims have not been proven, but the litigation may add investor uncertainty. Class action deadline notice
• Neutral Sentiment: A director sold 2,000 shares under a pre-arranged Rule 10b5-1 plan. The transaction was relatively small and scheduled in advance, so it may have limited significance on its own. Director share sale

About Doximity

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.